Evidence map›Paper›PMID 39377810›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Pharmacokinetic analysis and simplified uptake measures for tumour lesion [

Jessica E Wijngaarden, Maarten Slebe, Johanna E E Pouw, Daniela E Oprea-Lager, Robert C Schuit, Chris Dickhoff, Jelena Levi, Albert D Windhorst, C Willemien Menke-van der Houven van Oordt, Andrea Thiele and 3 more

Abstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. PD-L1 PET/CT imaging withEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Mitochondrial Imaging Detects Early Cardiac Changes Following Cancer Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  3. Review
  4. [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jessica E Wijngaarden *Department of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, Netherlands. j.e.wijngaarden@amsterdamumc.nl.ORCID 0000-0003-1486-6246
Maarten Slebe *Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.ORCID 0000-0001-8056-1235
Johanna E E PouwCancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
Daniela E Oprea-LagerDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Robert C SchuitDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Chris DickhoffDepartment of Cardiothoracic Surgery, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Jelena LeviCellSight Technologies Incorporated, San Francisco, CA, USA.
Albert D WindhorstDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
C Willemien Menke-van der Houven van OordtCancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
Andrea ThieleDepartment of Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
Idris BahceCancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
Ronald BoellaardDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Maqsood YaqubDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.

Funding

Boehringer Ingelheim Boehringer Ingelheim
6 · The paper itself

Abstract

introductionThe novel positron emission tomography (PET) imaging tracer, [

methodsTen patients with early-stage NSCLC and three patients with advanced NSCLC underwent a dynamic PET scan of minimal 60 min. Venous and/or arterial blood sampling was obtained at maximum seven time points. Tumour lesion time activity curves and metabolite-corrected input functions were analysed using single-tissue reversible (1T2k), two-tissue irreversible (2T3k) and two-tissue reversible (2T4k) plasma input models. Simplified uptake measures, such as standardised uptake value (SUV) and tumour-to-blood (TBR) or tumour-to-plasma ratio (TPR), were evaluated for different time intervals.

resultsWhole-blood and plasma radioactivity concentrations showed rapid clearance of [

conclusionTumour lesion [

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsPositron-Emission TomographyAgedBiological TransportFemaleHumansMaleMiddle AgedModels, Biological[18F]F-AraGActivated T-cellsImmunoPETPharmacokinetic modelling

Identifiers

PMID39377810
PMCPMC11732896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.